Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Date Issued
Submitting OIG
Department of Health & Human Services OIG
Other Participating OIGs
Department of Health & Human Services OIG
Agencies Reviewed/Investigated
Department of Health & Human Services
Report Number
OEI-03-17-00430
Report Type
Inspection / Evaluation
Agency Wide
Yes
Number of Recommendations
3
Questioned Costs
$0
Funds for Better Use
$0

Open Recommendations

This report has 2 open recommendations.
Recommendation Number Significant Recommendation Recommended Questioned Costs Recommended Funds for Better Use Additional Details
6683 No $0 $0

CMS should provide States with acquisition cost data for a wider range of specialty drugs.

6684 No $0 $0

CMS should Collaborate with States to conduct greater oversight of Medicaid MCOs’ management of specialty drugs; this oversightcould include a review of contract language that allows States to obtain requested information on specialty drug categorizations, specialty drug reimbursement methodologies, and cost management strategies.

Department of Health & Human Services OIG

United States